Use of Opportunistic Clinical Data and a Population Pharmacokinetic Model to Support Dosing of Clindamycin for Premature Infants to Adolescents
Daniel González(University of North Carolina at Chapel Hill), Michael Cohen‐Wolkowiez(Duke University), Kenneth C. Lewis, Brenda B. Poindexter(Cincinnati Children's Hospital Medical Center), Edmund V. Capparelli(University of California San Diego), Kevin Watt(University of Utah), Beth D. Harper(Clinical Research Institute), Chiara Melloni, Julie Autmizguine, Susan R. Mendley(University of Maryland, Baltimore), Daniel K. Benjamin(Duke University), Ram Yogev(Northwestern University), John E. Sullivan(University of Louisville), Adam J. Lewandowski(Nuffield Health)
Cited by 70
Related Papers
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach
|American Journal of Respiratory and Critical Care Medicine|2019|1.2k
Lymphocyte subsets in healthy children from birth through 18 years of age
|Journal of Allergy and Clinical Immunology|2003|828
Prevention and Management of Procedural Pain in the Neonate: An Update
|PEDIATRICS|2016|513